医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NCKU, Duke Collaborate to Better Design a Ventricular Assist Device

2015年12月24日 AM11:17
このエントリーをはてなブックマークに追加


 

TAINAN, Taiwan

A workshop involving doctors and researchers from National Cheng Kung University (NCKU) and Duke University School of Medicine was held on the morning of December 22 at the Heart Science and Medical Devices Research Center, NCKU. After workshop, they carried out an in-vivo test of the para-aortic blood pump (PABP) ventricular assist device implantation on calf.

Dr. Carmelo A. Milano, the Professor and Surgical Director for Heart Transplant and LVAD Program, Dr. Mani Daneshmand, Dr. Roberto Manson and Dr. Dawn E. Bowles from Duke University School of Medicine were invited by Prof. Pong-Jeu Lu, the inventor of PABP, to attend the workshop and surgery.

Lu has been leading his research team to develop the PABP for over 15 years. He said, PABP is a new type of left ventricular assist device which has completed major design, prototype manufacturing and testing after more than 10 years of effort.

He also noted that the PABP is designed to provide long-term counter-pulsation therapeutic support, minimize bleeding complication, and support the ultimate goal of bridge-to-recovery.

The current stage of design is focusing on simple and safe implantation for minimally invasive surgery, minimizing device and surgical costs to increase affordability, according to Lu.

“It has been significant improvement in the design and the deployment of the device,” said Daneshmand, adding “It’s getting closer to the intended goal which is a minimum invasive implant.”

He also said that they are very proud of how much effort Professor Lu and his team put into this excellent development.

Professor Lu mentioned the improvement in design of the blood pump from one-piece to two pieces.

Dr. Milano explained, “Having the device into two pieces made the introduction of the aorta easier, reducing the difficulty with the insertion for the device.”

“I think the device will be incredibly useful in American market,” said Dr. Manson adding, “It is simple and it has a function that none of the current devices have because it bridges to recovery.”

“And it’s reliable and inexpensive which would be not only good therapeutically but also doing a good to a lot of needy people,” he added.

Professor Lu noted, “Our goal is for first in human use in 2018.”

View source version on businesswire.com: http://www.businesswire.com/news/home/20151223005763/en/

CONTACT

National Cheng Kung University
Sonia Chuang, +886-6-275-7575 Ext.
50042
News Center
sonia20@mail.ncku.edu.tw

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 苏尔寿:IDS 2017出现仿冒品和专利侵权者——苏尔寿混合技术有限公司将继续行使其权利
  • New CDISC Standard Empowers Smarter Research for Diabetic Kidney Disease
  • Dr. Reddy’s and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections
  • Dr. Reddy’s Q1 FY18 Financial Results
  • Cogstate Receives Positive FDA Notification Regarding Medical Device Regulatory Submission